AI English summary of an SEC filing — figures as filed
AbbVie ABBVAbbVie said its reported GAAP and adjusted non-GAAP earnings for Q2 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis. The company said the expense represents an unfavorable impact of $0.52 per share on both GAAP and adjusted non-GAAP diluted earnings per share.
Key points
AI summaryAbbVie said its reported GAAP and adjusted non-GAAP earnings for Q2 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis. The company said the expense represents an unfavorable impact of $0.52 per share on both GAAP and adjusted non-GAAP diluted earnings per share.
The company said results for the quarter ended June 30, 2024 have not been finalized and are subject to its financial statement closing procedures. It said there can be no assurance that its final results will not differ from these preliminary estimates.
The company said it expects full-year 2024 adjusted diluted earnings per share guidance including the impact of acquired IPR&D and milestones expense for Q2 to be $10.61 to $10.81. Prior guidance excluding that expense was $11.13 to $11.33 per share (in millions, except per share data, in the table).
The company said its adjusted diluted earnings per share guidance range for Q2, including the impact of acquired IPR&D and milestones expense for Q2 2024, is $2.53 to $2.57. The previous guidance range, which excluded that expense, was $3.05 to $3.09 per share.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Acquired IPR&D and Milestones Expense $937 million
AbbVie said its reported GAAP and adjusted non-GAAP earnings for Q2 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis. The company said the expense represents an unfavorable impact of $0.52 per share on both GAAP and adjusted non-GAAP diluted earnings per share.
Source · Based on the filing body and exhibits
Q2 Results Are Preliminary Estimates Not Yet Finalized
The company said results for the quarter ended June 30, 2024 have not been finalized and are subject to its financial statement closing procedures. It said there can be no assurance that its final results will not differ from these preliminary estimates.
Source · Based on the filing body and exhibits
Full-Year Adjusted Diluted EPS Guidance $10.61 to $10.81
The company said it expects full-year 2024 adjusted diluted earnings per share guidance including the impact of acquired IPR&D and milestones expense for Q2 to be $10.61 to $10.81. Prior guidance excluding that expense was $11.13 to $11.33 per share (in millions, except per share data, in the table).
Source · Based on the filing body and exhibits
Q2 Adjusted Diluted EPS Guidance $2.53 to $2.57
The company said its adjusted diluted earnings per share guidance range for Q2, including the impact of acquired IPR&D and milestones expense for Q2 2024, is $2.53 to $2.57. The previous guidance range, which excluded that expense, was $3.05 to $3.09 per share.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…